Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Mundipharma Announces Launch of INVOKANA® and VOKANAMET® in Norway for the Treatment of Type 2 Diabetes as Part of Exclusive Distribution Agreement with Janssen
March 20, 2019 Off

Mundipharma Announces Launch of INVOKANA® and VOKANAMET® in Norway for the Treatment of Type 2 Diabetes as Part of Exclusive Distribution Agreement with Janssen

By BusinessWire

CAMBRIDGE, England–(BUSINESS WIRE)–The Mundipharma network of independent associated companies is pleased to launch the type-2 diabetes mellitus (T2DM) treatments Invokana®…

Synteract’s Continued Growth as a Leading CRO Results in Plans to Open Additional Office in Swansea, Wales
March 20, 2019 Off

Synteract’s Continued Growth as a Leading CRO Results in Plans to Open Additional Office in Swansea, Wales

By BusinessWire

CRO now recruiting for biostats, data management and other positions RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/CRO?src=hash” target=”_blank”gt;#CROlt;/agt;–Representatives from Synteract, an…

March 20, 2019 Off

2019 Innovations in Industrial Bioprocessing – Growing Demand of Freedom Foods – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Innovations in Industrial Bioprocessing” report has been added to ResearchAndMarkets.com’s offering. This edition of the Industrial Bio processing…

March 20, 2019 Off

Diabetes Drug Intelligence Center 2019: Global Database with Coverage Through 2012-2023 – Insulin Holds the Highest Market Share, and Sanofi, Novo Nordisk, and Eli Lilly Dominate – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Diabetes Drug Intelligence Center (2012-2023)” report has been added to ResearchAndMarkets.com’s offering. The Diabetes Drug Intelligence Center (IC)…

March 20, 2019 Off

2019 Innovations in Stem Cells, Cellular Therapies, Diabetes Therapy, Gene Therapies, Antiaging Research, Biomarkers, and Vaccines – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Innovations in Stem Cells, Cellular Therapies, Diabetes Therapy, Gene Therapies, Antiaging Research, Biomarkers, and Vaccines” report has been…

March 20, 2019 Off

Mergers & Acquisitions in the Global Life Sciences Industry, 2018-2019 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Mergers and Acquisitions in the Global Life Sciences Industry, 2018” report has been added to ResearchAndMarkets.com’s offering. The…

AbbVie puts multiple myeloma investigational treatmenttrial on hold after higher proportion of deaths was observed in the venetoclax
March 19, 2019 Off

AbbVie puts multiple myeloma investigational treatmenttrial on hold after higher proportion of deaths was observed in the venetoclax

By Dino Mustafić

AbbVie has put on hold clinical testing venetoclax (Venclexta/Venclyxto) for the investigational treatment of multiple myeloma, which being developed by AbbVie and Roche, and jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.

Novartis’ eye care division Alcon buys US-based private mdical device company for $285M
March 19, 2019 Off

Novartis’ eye care division Alcon buys US-based private mdical device company for $285M

By Dino Mustafić

Novartis’ eye care division Alcon has bought a privately-held US medical device company PowerVision, which focuses on focused on creating fluid-based intraocular lens implants, for $285 million at closing with additional payments based on specified regulatory and commercial milestones starting in 2023.

Amarin Corporation’s Vascepa significantly reduces total cardiovascular events in REDUCE-IT study
March 19, 2019 Off

Amarin Corporation’s Vascepa significantly reduces total cardiovascular events in REDUCE-IT study

By Dino Mustafić

Amarin Corporation’s Vascepa provided a statistically significant 30% risk reduction in total (first and subsequent) cardiovascular events compared to placebo in the statin-treated patient population studied in REDUCE-IT, as presented in a cardiovascular outcomes study.

Allergan expands label for Avycaz, for intra-abdominal infections
March 19, 2019 Off

Allergan expands label for Avycaz, for intra-abdominal infections

By Dino Mustafić

Allergan has expanded the label of Avycaz, as it got approval from the US FDA for its supplemental New Drug Application (sNDA), for treating young patients with complicated intra-abdominal infections.

Posts pagination

Previous 1 … 3,345 3,346 3,347 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine